| A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants LJ Scott, KL Mohlke, LL Bonnycastle, CJ Willer, Y Li, WL Duren, MR Erdos, ... science 316 (5829), 1341-1345, 2007 | 2899 | 2007 |
| Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes E Zeggini, LJ Scott, R Saxena, BF Voight, JL Marchini, T Hu, ... Nature genetics 40 (5), 638, 2008 | 1939 | 2008 |
| A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. G Shapiro, LS Rosen, AW Tolcher, JW Goldman, L Gandhi, ... Journal of Clinical Oncology 31 (15_suppl), 2500-2500, 2013 | 67 | 2013 |
| Wellcome Trust Case Control Consortium Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes E Zeggini, LJ Scott, R Saxena, BF Voight, JL Marchini, T Hu, PI De Bakker, ... Nat Genet 40 (5), 638-645, 2008 | 59 | 2008 |
| A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer LS Rosen, JW Goldman, AP Algazi, PK Turner, B Moser, T Hu, XA Wang, ... Clinical Cancer Research 23 (8), 1910-1919, 2017 | 26 | 2017 |
| Time-dependent cross ratio estimation for bivariate failure times T Hu, B Nan, X Lin, JM Robins Biometrika 98 (2), 341-354, 2011 | 22 | 2011 |
| Cross-ratio estimation for bivariate failure times with left truncation T Hu, X Lin, B Nan Lifetime data analysis 20 (1), 23-37, 2014 | 3 | 2014 |
| Interim results of a first-in-human phase 1 study of the oral Met kinase inhibitor, ly2801653, in patients with advanced cancer J Hwang, R Cohen, K Perez, H Safran, AR He, J Giles, T Hu, B Moser, ... CANCER RESEARCH 74 (19), 2014 | 1 | 2014 |
| Proportional cross-ratio model T Hu, B Nan, X Lin Lifetime data analysis 25 (3), 480-506, 2019 | | 2019 |
| Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer J Hwang, R Cohen, K Perez, H Safran, AR He, J Giles, T Hu, B Moser, ... Cancer Research 74 (19 Supplement), CT237-CT237, 2014 | | 2014 |
Xihong LinProfessor of Biostatistics and Professor of Statistics, Harvard UniversityDirección de correo verificada de hsph.harvard.edu
